Abstract
Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their antiinflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohns disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.
Keywords: Polyunsaturated fatty acids, inflammation, reumathoid arthritis, inflammatory bowel disease, Crohn disease, Ulcerative colitis
Current Pharmaceutical Design
Title: Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis
Volume: 15 Issue: 36
Author(s): C. Ruggiero, F. Lattanzio, F. Lauretani, B. Gasperini, C. Andres-Lacueva and A. Cherubini
Affiliation:
Keywords: Polyunsaturated fatty acids, inflammation, reumathoid arthritis, inflammatory bowel disease, Crohn disease, Ulcerative colitis
Abstract: Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their antiinflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohns disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.
Export Options
About this article
Cite this article as:
Ruggiero C., Lattanzio F., Lauretani F., Gasperini B., Andres-Lacueva C. and Cherubini A., Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909746
DOI https://dx.doi.org/10.2174/138161209789909746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and <i>In-vivo</i> Evaluation
Drug Delivery Letters The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19
Current Medicinal Chemistry Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Editorial (Hot Topic:Rheumatoid Arthritis: Current Advances in Pathogenesis, Diagnosis and Therapy)
Current Topics in Medicinal Chemistry The Study of Natural Compounds Targeting RANKL Signaling Pathway for the Treatment of Bone Diseases
Current Drug Targets Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracellular Nucleic Acids in Health and Disease
Current Pharmaceutical Biotechnology T-Cell-Mediated Signalling in Immune, Inflammatory and Angiogenic Processes: The Cascade of Events Leading to Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Mini-Reviews in Medicinal Chemistry Effect of Different Carriers on In Vitro and In Vivo Drug Release Behavior of Aceclofenac Proniosomes
Current Drug Delivery Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Activated Immune System and Inflammation in Healthy Ageing: Relevance for Tryptophan and Neopterin Metabolism
Current Pharmaceutical Design Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy Application of ImageJ Software for the Quantification of Hand Joint Space Narrowing in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Drug Repurposing: Translational Pharmacology, Chemistry, Computers and the Clinic
Current Topics in Medicinal Chemistry